Use of baloxavir marboxil post-exposure prophylaxis to halt an influenza A(H3) outbreak in a college sports team, November 2024
- PMID: 40127195
- DOI: 10.1093/cid/ciaf148
Use of baloxavir marboxil post-exposure prophylaxis to halt an influenza A(H3) outbreak in a college sports team, November 2024
Abstract
Baloxavir marboxil is approved for influenza treatment and post-exposure prophylaxis (PEP). There are limited real world examples of its use in influenza outbreaks. Here, we describe the use of Baloxavir marboxil as PEP to halt an influenza outbreak among a student athlete sports team during the 2024-2025 influenza season.
Keywords: Baloxavir; Influenza; Influenza post-exposure prophylaxis; Outbreak.
© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
LinkOut - more resources
Full Text Sources
Miscellaneous
